awmsg logo



afamelanotide (Scenesse®)


Reference No. 634


Appraisal information

afamelanotide (Scenesse®) 16 mg subcutaneous implant


Company: Clinuvel Pharmaceuticals Ltd
BNF category: Skin
NMG meeting date: 03/05/2017
AWMSG meeting date: Not scheduled
   
   
Submission Type: Full Submission
Status: Suspended
Advice No: Not available
Ministerial ratification: Not available

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

Indication

Prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP)
Preliminary Appraisal Recommendation (PAR)
Download
Company Response to the Preliminary Appraisal Recommendation (CR PAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download
Clinician and Patient Involvement Group (CAPIG) Meeting Summary
Download